Novo Nordisk Wins China Approval for Diabetes Drug

Novo Nordisk received SFDA approval for its latest diabetes drug, Victoza®, an injected treatment for type 2 diabetes. Victoza is the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analogue approved in China. Novo Nordisk said it will launch the drug in the second half of 2011. The drug's main competitor will be another GLP-1 agonist, Byetta, a diabetes treatment that Lilly brought to China in 2009. More details.... Stock Symbols: (NYSE: NVO)  (NYSE: LLY) Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});